Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer

Journal of Gastrointestinal Oncology

Volumn 7, Issue 6, 2016, Pages 982-988

  Kadokura, Makoto ^a   Ishida, Yasuaki ^a   Tatsumi, Akihisa ^a   Takahashi, Ei ^b   Shindo, Hiroko ^b   Amemiya, Fumitake ^a   Takano, Shinichi ^b   Fukasawa, Mitsuharu ^b   Sato, Tadashi ^b   Enomoto, Nobuyuki ^b  

^a Kofu Municipal Hospital   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Elderly patient; Neutrophil lymphocyte ratio (NLR); Pancreatic cancer (PC); Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADVERSE OUTCOME; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SAFETY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 85006992580     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.21037/jgo.2016.06.06     Document Type: Article

References (38)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
3. VItal Statistics Japan. Ministry of Health, Labour and Welfare. Available online: http://www.mhlw.go.jp/english/database/db-hw
4. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671-7.
5. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
6. Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc 1985;33:585-9.
7. Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA 1986;255:3385-90.
8. Hentic O, Dreyer C, Rebours V, et al. Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol 2011;17:3497-502.
9. Sehgal R, Alsharedi M, Larck C, et al. Pancreatic cancer survival in elderly patients treated with chemotherapy. Pancreas 2014;43:306-10.
10. Aldoss IT, Tashi T, Gonsalves W, et al. Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer-A Veterans Affairs Cancer Registry analysis. J Geriatr Oncol 2011;2:209-14.
11. Oziel-Taieb S, Faure M, Gilabert M, et al. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. J Gastrointest Cancer 2016;47:15-9.
12. Tas F, Sen F, Keskin S, et al. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival. Mol Clin Oncol 2013;1:788-92.
13. Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol 2014;20:10802-12.
14. Imaoka H, Mizuno N, Hara K, et al. Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study. Pancreas 2016;45:211-7.
15. Xue P, Kanai M, Mori Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med 2014;3:406-15.
16. Tabernero J, Chiorean EG, Infante JR, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist 2015;20:143-50.
17. Yi JH, Lee J, Park SH, et al. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology 2011;80:175-80.
18. Erdogan B, Turkmen E, Uzunoglu S, et al. Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma. Hepatogastroenterology 2013;60:1479-83.
19. Lim KH, Kim TY, Lee KH, et al. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. Cancer Chemother Pharmacol 2011;68:1017-26.
20. Tanaka T, Ikeda M, Okusaka T, et al. Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 2008;38:755-61.
21. Tas F, Sen F, Odabas H, et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013;18:839-46.
22. Szkandera J, Stotz M, Absenger G, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 2014;110:183-8.
23. Inal A, Kos FT, Algin E, et al. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study. J BUON 2012;17:102-5.
24. Lee KJ, Yi SW, Chung MJ, et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J 2013;54:643-9.
25. Martin LK, Wei L, Trolli E, et al. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early-or advanced-stage pancreas cancer. Med Oncol 2012;29:3101-7.
26. Ahmad J, Grimes N, Farid S, et al. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2014;13:474-81.
27. Ben Q, An W, Wang L, et al. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Pancreas 2015;44:471-7.
28. Cheng H, Long F, Jaiswar M, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis. Sci Rep 2015;5:11026.
29. Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013;109:416-21.
30. Szkandera J, Stotz M, Eisner F, et al. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS One 2013;8:e78225.
31. Maréchal R, Demols A, Gay F, et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas 2008;36:e16-21.
32. Jablonska J, Leschner S, Westphal K, et al. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010;120:1151-64.
33. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-94.
34. Salazar-Onfray F, López MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape.Cytokine Growth Factor Rev 2007;18:171-82.
35. Inoue D, Ozaka M, Matsuyama M, et al. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan. Jpn J Clin Oncol 2015;45:61-6.
36. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013;31:1640-8.
37. Stotz M, Szkandera J, Seidel J, et al. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. PLoS One 2014;9:e104730.
38. Tas F, Karabulut S, Bilgin E, et al. Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma. J Gastrointest Cancer 2013;44:404-9.